Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
Medicina (Kaunas)
; 57(12)2021 Nov 23.
Article
in English
| MEDLINE | ID: covidwho-1613898
ABSTRACT
Background and Objectives:
Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials andmethods:
88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic.Results:
The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081.Conclusions:
The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Peptides, Cyclic
/
Self Administration
/
Somatostatin
/
Octreotide
/
Neuroendocrine Tumors
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Medicina57121287
Similar
MEDLINE
...
LILACS
LIS